MorphoSys AG Shares Outstanding 2018-2021 | MOR

MorphoSys AG shares outstanding from 2018 to 2021. Shares outstanding can be defined as the number of shares held by shareholders (including insiders) assuming conversion of all convertible debt, securities, warrants and options. This metric excludes the company's treasury shares.
MorphoSys AG Annual Shares Outstanding
(Millions of Shares)
2020 133
2019 126
2018 125
2017 116
MorphoSys AG Quarterly Shares Outstanding
(Millions of Shares)
2021-06-30 141
2021-03-31 131
2020-12-31 133
2020-09-30 131
2020-06-30 131
2020-03-31 128
2019-12-31 126
2019-09-30 126
2019-06-30 126
2019-03-31 126
2018-12-31 125
2018-09-30 127
2018-06-30 124
2018-03-31 116
2017-12-31 115
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $1.709B $0.374B
MorphoSys AG is a biopharmaceutical company. It develops treatment for cancer, inflammations and autoimmune diseases. The company's proprietary portfolio consists of MOR208, MOR202, MOR103, MOR106 and MOR107. Its partnered programs lighthouse project includes Tremfya(R) and Gantenerumab. MorphoSys AG is based in Planegg, Germany.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $134.727B 8.97
Bio-Rad Laboratories (BIO.B) United States $23.483B 50.05
QIAGEN (QGEN) Netherlands $12.500B 21.17
Biohaven Pharmaceutical Holding (BHVN) United States $8.865B 0.00
Emergent Biosolutions (EBS) United States $2.891B 6.97
Arcus Biosciences (RCUS) United States $2.641B 0.00
Myovant Sciences (MYOV) United Kingdom $2.145B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.998B 0.00
Zymeworks (ZYME) Canada $1.380B 0.00
Ambrx Biopharma (AMAM) United States $0.521B 0.00
SQZ Biotechnologies (SQZ) United States $0.427B 0.00
Enzo Biochem (ENZ) United States $0.175B 51.71